Palbociclib (PD-0332991) HCl

Licensed by Pfizer Catalog No.S1116

Palbociclib (PD-0332991) HCl Chemical Structure

Molecular Weight(MW): 483.99

Palbociclib (PD-0332991) HCl is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays, respectively. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.

Size Price Stock Quantity  
USD 110 In stock
USD 170 In stock
USD 570 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

8 Customer Reviews

  • PD-0332991 causes inhibition of proliferation of EAC cells in a dose-dependent manner. Western blots showing the phosphorylation status of pRB at Ser780 and Ser795 after incubation with 125 nmol/L PD-0332991 for 24 and 72 hours. Reduction in cyclin A expression and the expression of RB2 (p130) tumor suppressor 72 hours after PD-0332991 treatment are shown (bottom). Total pRB (RB1) and actin are loading controls and T293 cell lysate (293) is a positive control for total pRB and phospho-pRB (Ph-RB). E, anchorage-independent growth of the 3 cell lines in the presence or absence (Cnt) of 125 nmol/L PD-0332991 for 3 weeks.

    Clin Cancer Res 2011 17(13), 4513-22. Palbociclib (PD-0332991) HCl purchased from Selleck.

    b, c MelJuso cells were treated for 12–48 h with 1 µM Selumetinib or 5 µM Palbociclib and the cells were fixed, stained with propidium iodide and cell cycle distribution was determined by flow cytometry (b) and whole cell extracts were fractionated by SDS-PAGE, transferred onto PVDF membrane and immuno-blotted with the indicated antibodies (c). Data is from a single experiment representative of three separate experiments with similar results. The data in (b) are mean ± S.D. from a single experiment with three replicate dishes of cell per data point; similar results were obtained in two additional experiments

    Cell Mol Life Sci, 2016, 73(4):883-900. Palbociclib (PD-0332991) HCl purchased from Selleck.

  • (A) Percentage of DN3a cells in S-phase (as gated on DAPI profile) from control (Zfp36l1/2fl/fl) and Zfp36l1/2fl/fl; CD2Cre (DCKO) mice, after 1 d of treatment with vector or palbociclib (drug).

    J Immunol, 2016, 197(7):2673-85. Palbociclib (PD-0332991) HCl purchased from Selleck.

     

    Patient tumor cell sensitivity to combinatorial treatment with histone deacetylase (HDAC)/cyclin-dependent kinase (CDK) inhibitors in 3-D culture. The effect of each drug or drug combination was assessed by fluorescent dye to identify live (green) and dead cells (red). Cells from breast reduction patients were used as non-cancer control in the assay.

    Pharmacogenomics J 2013 13(1), 94-104. Palbociclib (PD-0332991) HCl purchased from Selleck.

  •  

    Cdk4 is upregulated in ARMS and mMSCs transfected with PAX7-FKHR fusion gene (MP7F), and can be specifi cally inhibited. D: IF results showing overexpression of cdk4 in MP7F cells compared to parental mMSCs and reduced expression of cdk4 after treatment of MP7F cells with the cdk4 inhibitor, PD-0332991. E: IF results showing MyoD1 expression in parental mMSCs cells, and MP7F cells untreated and after treatment with the cdk4 inhibitor, PD-0332991.

    Clin Transl Oncol 2012 14(3), 197-206 . Palbociclib (PD-0332991) HCl purchased from Selleck.

    WM3734 melanoma cells were treated by PD-0332991 for 36 hours; melanoma cells treated by Doxorubicin (DXR)  at 0.5 μM is included as a control.

     

     

    Dr. Gao Zhang of University of Pennsylvania. Palbociclib (PD-0332991) HCl purchased from Selleck.

  • Serum-deprived T98G glioma cells are restimulated with serum(FBS) with or without 1 μΜ PD-0332991.

     

     

    Dr. Sabine Paternot and Dr Pierre Roger of IRIBHM, ULB, Brussels. Palbociclib (PD-0332991) HCl purchased from Selleck.

    P16INK4A knockdown in INK4A/ARF-wt human glioma cell LN319 potentiates PDGF-Apromoted anchorage-dependent growth in vitro. Soft agar growth of Ink4a/Arf-deficient mAst and LN444 cells treated with PD0332991. (A) IB analysis. (B) Quantification of soft agar assays. β-actin was used as a loading control in all IB experiments. Data are presented as mean ± s.d. and representative of two independent experiments. **, P < 0.01; ***, P < 0.001

    Dr. Kun-Wei Liu from University of Pittsburgh. Palbociclib (PD-0332991) HCl purchased from Selleck.

Purity & Quality Control

Choose Selective CDK Inhibitors

Biological Activity

Description Palbociclib (PD-0332991) HCl is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays, respectively. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.
Features Non-cytotoxic, and halts cancer cell growth & could be used in glioblastoma that has relapsed after temozolomide treatment (a chemotherapeutic used to treat many cancers).
Targets
CDK4/CyclinD3 [1]
(Cell-free assay)
CDK4/CyclinD1 [1]
(Cell-free assay)
CDK6/CyclinD2 [1]
(Cell-free assay)
9 nM 11 nM 15 nM
In vitro

PD 0332991 has little effect on other protein kinases including EGFR, FGFR, PGFR, IR. PD 0332991 is a non-ATP competitive inhibitor of Cdk4. PD 0332991 inhibits MDA-MB-435 breast carcinoma cells with IC50 of 66 nM, which is due to reduced Rb phosphorylation at Ser780. PD 0332991 inhibits thymidine incorporation into the DNA of Rb-positive human breast, colon, and lung carcinomas as well as human leukemias, with IC50 values ranging from 0.04-0.17 μM. PD 0332991 shows no activity in Rb-negative cells. PD 0332991 causes an accumulation of cells in G1 in MDA-MB-453 breast and Colo-205 carcinoma cells. [1] PD 0332991 also shows activity in 5T33MM myeloma cells (immunocompetent model) and sensitizes the cells to killing by bortezomib. [2] PD 0332991 inhibits luminal ER-positive as well as HER2-amplified breast cancer cell lines including MDA-MB-175, ZR-75-30, CAMA-1, MDA-MB-134, HCC-202 and UACC-893. PD 0332991 enhances the activity of tamoxifen and trastuzumab in these cell lines. PD 0332991 enhances the sensitivity of tamoxifen in the MCF7 tamoxifen-resistant cells. [3] A recent study shows that PD 0332991 could suppress malignant rhabdoid tumor (MRT) cell lines including MP-MRT-AN, KP-MRT-RY, G401, KP-MRT-NS and the sensitivity of the MRT cell lines to PD 0332991 is inversely correlated with expression of p16. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MOLM13 M{PEbmtqdmG|ZTDBd5NigQ>? NV63S3huOjRiaB?= MomwTY5pcWKrdHnvckBw\iCFRFu0JIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[gVoIheGixc4Doc5J6dGG2aX;uJJdqfGhiSVO1NEBw\iByLkCwNkDPxE1? NGCwdIgzPDZ2MUGwNy=>
COLO205 Mn7QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlzIO|IhcA>? MmjjRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{\XO|ZXSgZZMhcW6lb4Lwc5JifGmxbjDv[kBcO0ifdHj5cYllcW6nIHnueI8hTE6DIIfpeIghUUN3MDDv[kAxNjB|NjFOwG0> NY\mbWRnOjR4NEGxNFM>
U937 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFSyWXQ4OiCq MVLBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5Nme3OnZDDhd{BqdmOxcoDvdoF1cW:wIH;mJHs{UF22aIntbYRqdmViaX70c{BFVkFid3n0bEBKSzVyIH;mJFAvOTRizszN NWruVmNVOjR4NEGxNFM>
MOLM13 Mm\CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33nc|czKGh? MX;BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2RTF2xN{Bk\WyuczDoZZJjd3KrbnegSmxVOyCLVFSgcZV1[W62IHHzd4V{e2WmIHHzJIlv[2:{cH;yZZRqd25ib3[gX|NJZXSqeX3p[Ilv\SCrboTvJGRPSSC5aYToJGlEPTBib3[gNE4xQTZizszN M1TwXFI1PjRzMUCz
MOLM13 NEXve3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1W0U|czKGh? NF7IWY5CdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JJNwemGoZX7pZk1z\XOrc4ThcpQhcHWvYX6gUW9NVTF|IHPlcIx{KGG|c3Xzd4VlKGG|IHnuZ49zeG:{YYTpc44hd2ZiW{PIYZRpgW2rZHnu[UBqdnSxIFTORUB4cXSqIFnDOVAhd2ZiMD6wPVYh|ryP M1X4OVI1PjRzMUCz
MDA-MB-435 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVeyOEBp MnrtTWM2OD1yLkG2JO69VQ>? MnHVNVU5ODF6M{G=
K562 NHzsenNEgXSxdH;4bYMhSXO|YYm= NFvhbGE6PiCq NEXxXZRFVVOR NXSzcWRbUUN3ME2yJO69VQ>? M1jYblI1PDF5NU[2
DU145 NIXCWYtEgXSxdH;4bYMhSXO|YYm= MVG5OkBp MkXlSG1UVw>? NUTTNWN[UUN3ME23MlUh|ryP M4XDZVI1PDF5NU[2
MDA-MB-231 MnL1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2O1UFEh|ryP MmXrNlQhcA>? Ml:zSG1UVw>? NWPxPGpxS2WubDDjfYNt\SCjcoLld5Qh[XO|ZYPz[YQh[XNiYXPjeY12dGG2aX;uJIF1KEdzIIDoZZNm Ml3WNlQ1OTd3Nk[=
MCF7 NG[5b3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGLqdmYyKM7:TR?= MWSyOEBp NV;jOJM5TE2VTx?= MX;D[YxtKGO7Y3zlJIFzemW|dDDhd5Nme3OnZDDhd{Bi[2O3bYXsZZRqd25iYYSgS|EheGijc3W= NGjQ[YIzPDRzN{W2Oi=>
MCF7 M2fxbmtqdmG|ZTDBd5NigQ>? M3LkXFUh|ryP NEWyc4wzPCCq NFS4[YZFVVOR M4jWOGlvcGmkaYTpc44hd2ZicnXjc41jcW6jboSgR2RMPC:leXPsbY5FOSCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKHKndHnuc4Jt[XO2b33hJJBpd3OyaH;yfYxifGmxbjDheEBU\XJ5OEC= Mmf3NlQ1OTd3Nk[=
MDA-MB-231 MXTLbY5ie2ViQYPzZZk> MnvZOUDPxE1? M{TBS|I1KGh? MmHFSG1UVw>? NH3rbVFKdmirYnn0bY9vKG:oIILlZ49u[mmwYX70JGNFUzRxY4njcIlvTDFiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iC{ZYTpco9jdGG|dH;tZUBxcG:|cHjvdplt[XSrb36gZZQhW2W{N{iw MkmxNlQ1OTd3Nk[=
MDA-MB-231 MV\GeY5kfGmxbjDBd5NigQ>? NHTNPJoyNTFyIN88US=> MnO3NlQhcA>? NFrpRYJFVVOR MmD1[I9meyCwb4SgbY5lfWOnIHHwc5B1d3OrczDhd5Nme3OnZDDhd{BRSVKSIHPs[YF3[Wen M2XuRlI1PDF5NU[2
MCF7 M3K2NmZ2dmO2aX;uJGF{e2G7 MYexMVExKM7:TR?= MX2yOEBp M37iT2ROW09? NGX4Npdld2W|IH7veEBqdmS3Y3WgZZBweHSxc3nzJIF{e2W|c3XkJIF{KFCDUmCgZ4xm[X[jZ3W= MVmyOFQyPzV4Nh?=
MDA-MB-231 NH7DTmJHfW6ldHnvckBCe3OjeR?= NEnz[GsxNjVvMTFOwG0> MofoOFghcA>? NXzGemI6TE2VTx?= M{[wOIhieyCwbzDD[YxtKGO7Y3zlJIFzemW|dDDhd5Nme3OnZDDhd{Bi[2O3bYXsZZRqd25iYYSgd5VjNUdzIIDoZZNm M{\FW|I1PDF5NU[2
MCF7 M4XpO2Z2dmO2aX;uJGF{e2G7 M2rQRlAvPS1zIN88US=> MYC0PEBp NYDx[Yx2TE2VTx?= NF\3e4Fp[XNibn:gR4VtdCCleXPs[UBienKnc4SgZZN{\XO|ZXSgZZMh[WOldX31cIF1cW:wIHH0JJN2[i2JMTDwbIF{\Q>? MnXGNlQ1OTd3Nk[=
697 NEHV[3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\YcpFKSzVyPUG0PE4{QCCwTR?= NGTYUmpUSU6JRWK=
P12-ICHIKAWA M2Licmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{TtOWlEPTB;OU[uNFQhdk1? Ml7mV2FPT0WU
NB69 MnvxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\OTWM2OD1zNkGuPEBvVQ>? M3qyT3NCVkeHUh?=
EoL-1 MlqzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\vSW5yUUN3ME2xPFcvOjZibl2= NIPs[I9USU6JRWK=
BHT-101 M3LjS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnEVYNKSzVyPUG5PE4zPSCwTR?= MYrTRW5ITVJ?
SK-NEP-1 Mof6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlnYTWM2OD1{MkCuNFIhdk1? MnnoV2FPT0WU
MHH-NB-11 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn3uTWM2OD1{MkCuNVkhdk1? MXjTRW5ITVJ?
AsPC-1 NWO2U4U1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1HEe2lEPTB;MkWyMlU{KG6P M1TmNnNCVkeHUh?=
ES1 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXXJR|UxRTJ3Nj6yOUBvVQ>? M1m5WnNCVkeHUh?=
LAMA-84 M1jGPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV\JR|UxRTJ3OD6xPUBvVQ>? MVjTRW5ITVJ?
MOLT-16 Mn[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3rlWmlEPTB;MkW4MlQ6KG6P M4XWcHNCVkeHUh?=
ES7 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlLVTWM2OD1{N{OuNFkhdk1? MX7TRW5ITVJ?
KY821 M{jDOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTNzND6xJI5O NXmz[IZnW0GQR1XS
RT-112 NHnTVGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF20cXJKSzVyPUOyNU4xPSCwTR?= MYfTRW5ITVJ?
HL-60 MnryS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHGweY1KSzVyPUO0NE43PiCwTR?= NVvNbHJZW0GQR1XS
MOLT-4 NYi5OHJyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHLQeVVKSzVyPUO0OU4yOyCwTR?= M1nxPHNCVkeHUh?=
KARPAS-45 NWrZRmJqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTN5Nj6xOkBvVQ>? NIT3dZFUSU6JRWK=
SK-N-AS NWnRemxuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3RWGxWUUN3ME2zPFcvQDNibl2= M1jFNnNCVkeHUh?=
CTB-1 NEjZOppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPYTWM2OD12MEWuNFIhdk1? MULTRW5ITVJ?
NKM-1 M3\PUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7mOINSUUN3ME20NVEvQDlibl2= MljXV2FPT0WU
HTC-C3 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fNUGlEPTB;NEOyMlk2KG6P M37QfHNCVkeHUh?=
BE-13 NYLuZ3pxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTR2ND6yO{BvVQ>? MnHDV2FPT0WU
KOSC-2 M3jjbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{jBXmlEPTB;NE[2Mlkhdk1? MlLuV2FPT0WU
NB14 NF3OdI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTR6Mz61PEBvVQ>? NFTSd5ZUSU6JRWK=
CAL-27 NF:ze4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\Xe|FKUUN3ME20PVQvPTlibl2= MXLTRW5ITVJ?
H9 Mn\zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTR7NT60N{BvVQ>? MWXTRW5ITVJ?
RS4-11 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\wO2lEPTB;NUC0Mlc{KG6P NF;Z[mRUSU6JRWK=
PA-1 MoTGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTVyOT64OkBvVQ>? MorqV2FPT0WU
MV-4-11 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnTkTWM2OD13MUOuPFUhdk1? MmHPV2FPT0WU
OS-RC-2 M4DQTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVzIR5A2UUN3ME21NlEvPjJibl2= Mo\zV2FPT0WU
RPMI-8226 NGTqS49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1X4UmlEPTB;NUK2Mlg3KG6P NH6yS5ZUSU6JRWK=
HGC-27 M1OzW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWHM[4NlUUN3ME21OlQvQTlibl2= M1TrfnNCVkeHUh?=
CHP-212 MmTkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEnJToJKSzVyPUW5N{42QSCwTR?= NVHaUXVKW0GQR1XS
NB10 MnziS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUjx[VlLUUN3ME21PVkvOThibl2= NGn5So9USU6JRWK=
HH NYrBUlZMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlzJTWM2OD13OUmuOFMhdk1? MVnTRW5ITVJ?
EW-16 M2LKdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mkn3TWM2OD14MEOuOVIhdk1? NUD3dWp{W0GQR1XS
ES8 M37rNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;YNXlnUUN3ME22NFUvOjFibl2= MXLTRW5ITVJ?
HAL-01 NXS5c|dtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTZyNT62O{BvVQ>? NELlSodUSU6JRWK=
A204 M3TNcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHW1OldKSzVyPU[zN{46OSCwTR?= M4fhfHNCVkeHUh?=
MHH-PREB-1 NVrRcGNCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTZ|Nj65PUBvVQ>? M1XMWHNCVkeHUh?=
EM-2 M1r6UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\LV4lkUUN3ME22OVAvPjRibl2= MkDEV2FPT0WU
BV-173 M3LRcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlnMTWM2OD14NUKuOFghdk1? NU\lOYRxW0GQR1XS
ONS-76 Mn;nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTZ5Nz64NkBvVQ>? MXLTRW5ITVJ?
KM-H2 NWTsbJVtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoDGTWM2OD14OUWuOVQhdk1? MYPTRW5ITVJ?
D-263MG M2jKbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MonFTWM2OD15MUeuNVIhdk1? NY\2SIxwW0GQR1XS
ES3 M2jt[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTd{OD65N{BvVQ>? NH3GWGNUSU6JRWK=
VA-ES-BJ MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2fiOGlEPTB;N{OyMlI4KG6P NIjEeG5USU6JRWK=
NBsusSR NX;6VGxUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFfZTIZKSzVyPUe0Nk46QSCwTR?= M1;HN3NCVkeHUh?=
NCI-H520 MmjhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4DCXGlEPTB;N{S2MlUzKG6P M3\4SXNCVkeHUh?=
ES5 MkPwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHTuZ3VKSzVyPUe1Nk45KG6P NFXMfIRUSU6JRWK=
T-24 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWDzUlBHUUN3ME23O|gvPzFibl2= Mn\uV2FPT0WU
SW962 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MojDTWM2OD16MEiuOlMhdk1? MlvRV2FPT0WU
EW-3 M{DTPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWfJR|UxRThyOD63OkBvVQ>? Mn6yV2FPT0WU
RXF393 M1zBN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoXiTWM2OD16MUKuO|khdk1? NI\rcFZUSU6JRWK=
U251 NXTxdYdmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1X0WmlEPTB;OEGzMlg5KG6P NGe1eGtUSU6JRWK=
CAMA-1 MlnvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVvwNXpPUUN3ME24N|MvQTRibl2= MmnrV2FPT0WU
JVM-3 NF;sbW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;3cWRNUUN3ME24OVEvPzhibl2= NVHvO5VYW0GQR1XS
COLO-800 M2\6SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHJR|UxRTh7Nz63PEBvVQ>? NIXyVHhUSU6JRWK=
OVCAR-5 NUXNSmJtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnH0TWM2OD17MECuNUBvVQ>? NEXNc4NUSU6JRWK=
LB1047-RCC NXHVOm5{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTl{Nz61OkBvVQ>? NVfIPJl7W0GQR1XS
SW954 NVLtTGxXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIHMS|ZKSzVyPUmyPU41OSCwTR?= MkW5V2FPT0WU
J-RT3-T3-5 NFXhOFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MofITWM2OD17M{[uNFYhdk1? MlXwV2FPT0WU
Mewo M3LQTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEjJO21KSzVyPUmzOk43KG6P NES1XWNUSU6JRWK=
NCI-H1770 M2HmOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHG2ZlVKSzVyPUm0NE42PSCwTR?= NF3kZmNUSU6JRWK=
HO-1-N-1 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEizUnJKSzVyPUm2Nk45OSCwTR?= MoDnV2FPT0WU
HSC-3 NVTDUJpET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVnic215UUN3ME25OlYvPDhibl2= NYLC[ZFKW0GQR1XS
TYK-nu MlztS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3oTWM2OD17OUiuNlUhdk1? NGHpTYxUSU6JRWK=
KYSE-150 MnfzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGXN[FRKSzVyPUGuNFAxPzZizszN MnHtV2FPT0WU
SN12C MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIHxS|ZKSzVyPUGuNFA5PzVizszN MYTTRW5ITVJ?
MOLT-13 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7QWINKSzVyPUGuNFE1OjFizszN NVvRbW52W0GQR1XS
TE-11 NVrN[3l7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTFwMES4NVIh|ryP NWjnVnpSW0GQR1XS
DB M2jheWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTFwMEeyO|Mh|ryP NEDhN4pUSU6JRWK=
CAL-39 NVXsOXhWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH7XR4tKSzVyPUGuNFc2OjJizszN MXrTRW5ITVJ?
A3-KAW MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTFwMEi0NFgh|ryP NITKNndUSU6JRWK=
CHP-134 NETJWZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml\QTWM2OD1zLkGxPFA4KM7:TR?= MYDTRW5ITVJ?
TGW MkLYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MknzTWM2OD1zLkGyN|k2KM7:TR?= MnjTV2FPT0WU
QIMR-WIL NWO3XIMzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2G3SGlEPTB;MT6xN|E{PCEQvF2= NIDyeVlUSU6JRWK=
NCI-SNU-1 M33kb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnTMTWM2OD1zLkG2N|U1KM7:TR?= NVnHfHdKW0GQR1XS
CGTH-W-1 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEDBO5RKSzVyPUGuNVcyQDZizszN NY[4NoRiW0GQR1XS
MHH-ES-1 NFOzdVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1rkU2lEPTB;MT6xO|k5PiEQvF2= MVXTRW5ITVJ?
LB2241-RCC NXT1ZXh1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHn0N4tKSzVyPUGuNVg3OiEQvF2= MmD2V2FPT0WU
ML-2 NGLyO5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3K2NGlEPTB;MT6yNFc{PCEQvF2= NHnw[3ZUSU6JRWK=
COR-L23 MnL0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3zTWM2OD1zLkKyPVM{KM7:TR?= NGCzZmVUSU6JRWK=
BFTC-905 MlXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{PnR2lEPTB;MT6yOFI3PyEQvF2= MUnTRW5ITVJ?
Hs-578-T NXOzWldmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTFwMkW4NVch|ryP Mny4V2FPT0WU
KG-1 NFHlO3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnzQTWM2OD1zLkK2Olg3KM7:TR?= NW\1O2R[W0GQR1XS
HEL NFf3O5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{T5RmlEPTB;MT6yPVM{QCEQvF2= MYrTRW5ITVJ?
A549 M{fJTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3fhUGlEPTB;MT6yPVM6QSEQvF2= NVuwbY9NW0GQR1XS
COLO-741 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{PwVGlEPTB;MT6zNlA5QSEQvF2= NFvIOpdUSU6JRWK=
PC-3 M3fEbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHlTWM2OD1zLkO1NlIyKM7:TR?= M4[5OnNCVkeHUh?=
HOS NVTJTmF7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTFwM{WyPVYh|ryP MkjQV2FPT0WU
HT-1080 NYjRbHVmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\uVWlEPTB;MT6zO|UyQSEQvF2= MX3TRW5ITVJ?
TE-8 NXjyOnRsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGPmc4FKSzVyPUGuOFE4PzRizszN NXew[WxSW0GQR1XS
BHY MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDiXHhpUUN3ME2xMlQ3QTJ|IN88US=> NGHFUYhUSU6JRWK=
BB65-RCC NFPNbZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXnJR|UxRTFwNUC1Nlgh|ryP MmXBV2FPT0WU
HN MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2fj[GlEPTB;MT61OFA4OSEQvF2= MYLTRW5ITVJ?
NCI-H441 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;ae3JKSzVyPUGuOVQ6ODdizszN NI\mWW5USU6JRWK=
RPMI-8866 M1rzc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGH6cZRKSzVyPUGuOVg2ODdizszN NH3wW5VUSU6JRWK=
CAL-62 MnznS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlvuTWM2OD1zLk[wPFYzKM7:TR?= NIHXcHhUSU6JRWK=
MG-63 M3PsTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXTOWW97UUN3ME2xMlYyQDF|IN88US=> MYfTRW5ITVJ?
SK-LU-1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2TsdWlEPTB;MT62NlE2OiEQvF2= NGCwblVUSU6JRWK=
BCPAP NHH2UHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTFwNk[0OVch|ryP M2LoSHNCVkeHUh?=
22RV1 M1\zbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEGzbZdKSzVyPUGuOlc5PDNizszN M1e1PHNCVkeHUh?=
T47D NIrXcllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\zbmlEPTB;MT62PFA3OSEQvF2= MUjTRW5ITVJ?
MSTO-211H NV7CXZZLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWDJR|UxRTFwNkm2NFMh|ryP NUnmV4NpW0GQR1XS
DEL NFKxfndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4jSVWlEPTB;MT63NFI4OyEQvF2= M3jrTnNCVkeHUh?=
H4 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFvuPVJKSzVyPUGuO|MzOTJizszN M{fnS3NCVkeHUh?=
CAL-51 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmiyTWM2OD1zLke0PFU2KM7:TR?= MYHTRW5ITVJ?
ABC-1 MnWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MorJTWM2OD1zLke4OVgzKM7:TR?= M3zHWnNCVkeHUh?=
MZ2-MEL NVe4cm93T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoHTTWM2OD1zLke5OVQzKM7:TR?= NGTpfm9USU6JRWK=
YKG-1 Mm\iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTFwOEGwOlEh|ryP NYWwe4RqW0GQR1XS
KM12 M2Lnbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmrETWM2OD1zLkixOlAzKM7:TR?= NGXwXoFUSU6JRWK=
L-363 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnm5TWM2OD1zLki3OFEzKM7:TR?= MlvaV2FPT0WU
KU812 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkHETWM2OD1zLki5NlgzKM7:TR?= NFvzPY9USU6JRWK=
LOXIMVI NXLTdVV2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVH4SZdoUUN3ME2xMlkyOjJ6IN88US=> MWXTRW5ITVJ?
G-401 NETq[2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXXYXm9IUUN3ME2xMlkzPDJ6IN88US=> M3PTdnNCVkeHUh?=
SW780 MoLzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTFwOU[yOFYh|ryP M1vmRXNCVkeHUh?=
SW872 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWLFNG5rUUN3ME2xMlk5OzNizszN M2Ptc3NCVkeHUh?=
NB7 M{nNb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4rLeWlEPTB;MT65PVMzOyEQvF2= NH3iRnpUSU6JRWK=
T98G M3LpTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXnEPGw1UUN3ME2yMlAxPjZ4IN88US=> NEO0NGJUSU6JRWK=
SW1710 M{LGO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHJR|UxRTJwME[5OFUh|ryP M3\xS3NCVkeHUh?=
NCI-H1573 MkPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1rqRWlEPTB;Mj6wO|I6QCEQvF2= NXTuUZdNW0GQR1XS
KE-37 M{[xZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2nRbGlEPTB;Mj6wPFk2OSEQvF2= MlzBV2FPT0WU
786-0 M1TtU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXq1ToRFUUN3ME2yMlE2PDN7IN88US=> MVfTRW5ITVJ?
SAS MlzIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVS1N2N[UUN3ME2yMlIxOzd2IN88US=> MUXTRW5ITVJ?
CAL-54 M4TIRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3fzU2lEPTB;Mj6yNFQyOyEQvF2= M2HvXHNCVkeHUh?=
SF268 M4\mPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHTz[XVKSzVyPUKuNlMyOjJizszN MU\TRW5ITVJ?
SW620 NIjUXnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\Pc3JRUUN3ME2yMlI3OTZ7IN88US=> MmfLV2FPT0WU
MN-60 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4rMT2lEPTB;Mj6zNVA3KM7:TR?= NH\qN5lUSU6JRWK=
EFO-27 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHfXZnZKSzVyPUKuN|IxPThizszN MnnvV2FPT0WU
NCI-H747 MkHKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTJwM{KxPVkh|ryP MVXTRW5ITVJ?
HCC2218 NF;qclhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3i4cWlEPTB;Mj6zOVM4PCEQvF2= MoPOV2FPT0WU
MIA-PaCa-2 NI\uNmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjmN2dKSzVyPUKuN|Y1OzdizszN MULTRW5ITVJ?
SJSA-1 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIfMXmxKSzVyPUKuN|c4QTZizszN M2\JbnNCVkeHUh?=
RKO NVPOcYluT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXq2S4g{UUN3ME2yMlM5PDl4IN88US=> MXXTRW5ITVJ?
NB6 M3\2Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHKTWM2OD1{LkSwN|c1KM7:TR?= MlH4V2FPT0WU
ES4 M2O2R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTJwNEW0NlIh|ryP NXy3UFZlW0GQR1XS
EGI-1 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4ra[WlEPTB;Mj60Olg5OyEQvF2= MmHDV2FPT0WU
CTV-1 Mnz0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4PO[2lEPTB;Mj61Nlc4OyEQvF2= NEPDNmlUSU6JRWK=
NCI-H1355 NXLrS|ZYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTJwNUW5OVEh|ryP MVvTRW5ITVJ?
GT3TKB MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGC1UY9KSzVyPUKuOVkyQTlizszN M37i[HNCVkeHUh?=
SK-HEP-1 MoGzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NELZbG5KSzVyPUKuOVkzPjZizszN NXT6b2xEW0GQR1XS
GAMG Ml7MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHrNY9KSzVyPUKuOVk{QTRizszN M2HNSHNCVkeHUh?=
SK-MES-1 NYPsUW5lT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3n3T2lEPTB;Mj62NVgxOyEQvF2= M13tdXNCVkeHUh?=
RO82-W-1 NVm0cVllT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml\NTWM2OD1{Lk[yNFU4KM7:TR?= M1fJW3NCVkeHUh?=
ECC10 MmnMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTJwN{CyNFYh|ryP MnjjV2FPT0WU
MCF7 NGrLenZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWPqU5JZUUN3ME2yMlcyPDZ2IN88US=> NH3GXFRUSU6JRWK=
D-283MED NX[3flZoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NILDfYNKSzVyPUKuO|I1OyEQvF2= MnmzV2FPT0WU
RPMI-7951 M4DUd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTJwN{W2PVQh|ryP M4\LVXNCVkeHUh?=
Ramos-2G6-4C10 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTJwN{ewPVkh|ryP M4f1TXNCVkeHUh?=
KGN MoLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTJwOEG4PFQh|ryP NX\CTVFtW0GQR1XS
NUGC-3 M1HMTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1LGV2lEPTB;Mj64NlUxPSEQvF2= NVj2R3RSW0GQR1XS
NCI-H292 M4r0T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmjGTWM2OD1{Lki1NFU{KM7:TR?= MnvVV2FPT0WU
Becker Mlv4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXXxNYxiUUN3ME2yMlk2QDN{IN88US=> M2roR3NCVkeHUh?=
NCI-H1299 Mn61S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHvvTJNKSzVyPUOuNFUzPjNizszN NXLOPGVbW0GQR1XS
ETK-1 M{jBTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmjFTWM2OD1|LkC1OFMh|ryP NVG2NmZuW0GQR1XS
TK10 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI\JemxKSzVyPUOuNlAyPjVizszN MX3TRW5ITVJ?
VMRC-RCZ NEToUVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnGXZJZUUN3ME2zMlM3PDh6IN88US=> M1\USHNCVkeHUh?=
YH-13 NU\5RW5GT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NILsTWVKSzVyPUOuOFQxPzlizszN NEfkbIFUSU6JRWK=
DU-145 M1\CXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoTVTWM2OD1|LkS2NlY6KM7:TR?= NVnqfXlZW0GQR1XS
SW1088 NEj6UnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFvPNW5KSzVyPUOuOFc1PyEQvF2= NXfPc4NGW0GQR1XS
HOP-92 M{i0W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVH0NnVZUUN3ME2zMlUxOzR{IN88US=> NWXGSldMW0GQR1XS
KP-N-YS Mlf0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MofOTWM2OD1|Lk[yNVM6KM7:TR?= MXjTRW5ITVJ?
NCI-H460 M2fJXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlroTWM2OD1|Lk[2O|Mh|ryP M4fyenNCVkeHUh?=
U-2-OS NGLPcpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml32TWM2OD1|LkeyOVM2KM7:TR?= M4e4ZXNCVkeHUh?=
A101D M{CyXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmruTWM2OD1|Lke2PVM3KM7:TR?= M2XUXnNCVkeHUh?=
MDA-MB-231 NVzkeG1WT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVKzRnlsUUN3ME2zMlgyQTVzIN88US=> M2fRfXNCVkeHUh?=
IST-MES1 NE\CTHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mom2TWM2OD1|LkizNkDPxE1? NWTzNG5jW0GQR1XS
COR-L105 NVvIV5VuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml\6TWM2OD12LkCxPEDPxE1? MVTTRW5ITVJ?
NCI-H1437 NInzfYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWTVXpdEUUN3ME20MlAzOzB{IN88US=> M13XUXNCVkeHUh?=
CAL-85-1 MkPXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUmx[3NXUUN3ME20MlAzPDZzIN88US=> NFfPN4JUSU6JRWK=
MZ1-PC NWXrfpc3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIj0Wm9KSzVyPUSuNVg2PTZizszN NVrZR2NQW0GQR1XS
VM-CUB-1 MkfSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTRwM{GyPFQh|ryP NWq1dZY5W0GQR1XS
CHL-1 MlfKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2fPSWlEPTB;ND6zNlE3QSEQvF2= M4f1fHNCVkeHUh?=
MDA-MB-361 M{H1cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIjNPIxKSzVyPUSuN|MyPTNizszN NY[wZnozW0GQR1XS
NCI-H661 NYHG[295T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkXBTWM2OD12LkWwNFkzKM7:TR?= NYnhUJBIW0GQR1XS
EW-11 M1TCSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnrmTWM2OD12LkWyNlMyKM7:TR?= MVjTRW5ITVJ?
BEN MlHkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;OeGlEPTB;ND61NlgyPSEQvF2= MYnTRW5ITVJ?
BFTC-909 MoGyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlfzTWM2OD12LkW2Nlc2KM7:TR?= NIXWRnJUSU6JRWK=
NCI-H2087 MkDLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoHjTWM2OD12LkW4NVY1KM7:TR?= M2n6VHNCVkeHUh?=
RVH-421 MlXRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXni[IlZUUN3ME20MlY3PjlizszN NWXrNVd5W0GQR1XS
P30-OHK M2\hRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3TJTmlEPTB;ND62PFAxQCEQvF2= NW\XXox1W0GQR1XS
NCI-H28 NX7SPJBNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTRwOEG2OlEh|ryP NYDm[mYyW0GQR1XS
ES6 MkXMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGXVfZFKSzVyPUSuPFMxOTZizszN NGTRfFFUSU6JRWK=
769-P M{fiN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{PiOGlEPTB;ND64OVkzPiEQvF2= MXjTRW5ITVJ?
OE33 M{fyZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYHEd|VUUUN3ME20Mlg5OTZzIN88US=> MnXTV2FPT0WU
SW982 MljqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4T0WmlEPTB;ND65OVA3OSEQvF2= Mmr0V2FPT0WU
A388 NIjZPYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\LNXBzUUN3ME21MlAzQTh|IN88US=> NYm2UpR1W0GQR1XS
TI-73 NHvUSYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTVwME[xPVQh|ryP NYDrV5pKW0GQR1XS
HCT-116 NWKz[YpqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTVwMEm4PFkh|ryP MmfYV2FPT0WU
HuP-T3 MkHES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWPreG9GUUN3ME21MlE5PzB7IN88US=> MXLTRW5ITVJ?
G-402 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUHqPYhlUUN3ME21MlE6PDF4IN88US=> NEPzUW1USU6JRWK=
NCI-H1792 NW\qS5BbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX32SGFGUUN3ME21MlI1PjJ{IN88US=> M{LaeXNCVkeHUh?=
NCI-H209 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTVwMkW5OFIh|ryP MUPTRW5ITVJ?
NCI-H1650 NV:1VFlZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEfyPZpKSzVyPUWuN|A3OzRizszN NFf6eG5USU6JRWK=
LCLC-97TM1 NEnPdWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF21[m9KSzVyPUWuN|E5ODhizszN MmLBV2FPT0WU
S-117 Mme0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF7wVJNKSzVyPUWuN|Y6PzZizszN MoTVV2FPT0WU
GI-ME-N MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmS1TWM2OD13LkO5OlgyKM7:TR?= MorCV2FPT0WU
NCI-H2122 M2PU[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTVwNEmzPVch|ryP NXOzUXZTW0GQR1XS
NCI-H1793 NFjNUlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEL2XXRKSzVyPUWuOlc2QTNizszN NVvFb25XW0GQR1XS
C2BBe1 Mm\OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkPGTWM2OD13LkewNFg5KM7:TR?= M2XodHNCVkeHUh?=
TE-12 MnjCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jxRWlEPTB;NT64NFU2PiEQvF2= MmeyV2FPT0WU
LCLC-103H NHfJSoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnLHTWM2OD13LkmxO{DPxE1? Moi2V2FPT0WU
A673 NWDRNFg4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG[4cldKSzVyPUWuPVE6OzJizszN NEexNGNUSU6JRWK=
BB30-HNC M2fzOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\nbGlEPTB;NT65PFM3KM7:TR?= M4PqTHNCVkeHUh?=
SF295 M3i3Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1OxemlEPTB;Nj6wNFQzOiEQvF2= NUTJXnhIW0GQR1XS
KU-19-19 NXLEW5hMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3HreWlEPTB;Nj6wNVc{OSEQvF2= NV7xOJNbW0GQR1XS
CFPAC-1 NEWzTW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NILhUXVKSzVyPU[uNFQ1PDNizszN M1X1[nNCVkeHUh?=
LoVo MnzlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYCzVVNPUUN3ME22MlA2ODZ|IN88US=> NHPWW5JUSU6JRWK=
8505C NX\He4FRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTZwMEe1O|Mh|ryP NVrKR4tkW0GQR1XS
GMS-10 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1fRfWlEPTB;Nj6xOVAxOiEQvF2= M{L0RnNCVkeHUh?=
Ca9-22 NF23c49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHKyPYpKSzVyPU[uNVY4OSEQvF2= NWDsNFcxW0GQR1XS
DOK NGjLOJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Moi0TWM2OD14LkKyNFczKM7:TR?= NUHjR4Y5W0GQR1XS
FADU NEmxRlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRTZwMk[wN|kh|ryP M{DkenNCVkeHUh?=
BxPC-3 MknXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4XobGlEPTB;Nj6yO|MzKM7:TR?= M3zMR3NCVkeHUh?=
CAL-33 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoW3TWM2OD14LkK5NlAyKM7:TR?= NV64d4IxW0GQR1XS
SHP-77 NY\RT2VuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{DReWlEPTB;Nj6zNVUyOiEQvF2= MUHTRW5ITVJ?
LXF-289 NVnKN|ZrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\STWM2OD14LkOzOFU2KM7:TR?= MkOwV2FPT0WU
GB-1 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1zP[mlEPTB;Nj6zPFIh|ryP NHfSeppUSU6JRWK=
KS-1 M4SzNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoTmTWM2OD14LkO4OFQ4KM7:TR?= MULTRW5ITVJ?
D-502MG MlLKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4qxNmlEPTB;Nj60NlM4PiEQvF2= MVrTRW5ITVJ?
LAN-6 NHTXSY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEHLbJFKSzVyPU[uOVExOjNizszN M2TZVnNCVkeHUh?=
H-EMC-SS NWL0[GVPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWf2UpkyUUN3ME22MlU3OTR5IN88US=> MUfTRW5ITVJ?
LC-2-ad NILSVFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEnhbolKSzVyPU[uOlAxPzZizszN NVTrR3ZxW0GQR1XS
NCI-H1693 M4PTZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHjWfoRKSzVyPU[uOlIzOTVizszN M3:wdnNCVkeHUh?=
SK-N-FI NGfJZ3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXzWUmoxUUN3ME22Mlc2ODR2IN88US=> M1fKRXNCVkeHUh?=
D-423MG M3;hXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NETBO3dKSzVyPU[uO|YyOTdizszN NEH3cphUSU6JRWK=
KNS-42 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2fQUWlEPTB;Nj63PFE6PyEQvF2= M3XRdXNCVkeHUh?=
GCT M3\QTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1zNUWlEPTB;Nj65N|gh|ryP NXznTGRmW0GQR1XS
DSH1 NUe2OGJST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGjTV4ZKSzVyPUeuNFY{OyEQvF2= MV7TRW5ITVJ?
D-247MG NVKyd|FsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmH5TWM2OD15LkC3PFgyKM7:TR?= NFPOWFVUSU6JRWK=
NCI-SNU-5 NWO1c|hkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NInv[ldKSzVyPUeuNVg{PzFizszN NVzLS246W0GQR1XS
TE-6 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVTRPJM5UUN3ME23MlIxPjBzIN88US=> M4DKVnNCVkeHUh?=
NOMO-1 M33aUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYO3cWp7UUN3ME23MlIzOTJ5IN88US=> MVXTRW5ITVJ?
NB17 MnnKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHUNoFKSzVyPUeuN|A{ODlizszN NYPNdmtYW0GQR1XS
EW-22 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTdwM{SzOFgh|ryP MUjTRW5ITVJ?
EW-13 NUHEfYNMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGLZNI9KSzVyPUeuN|UyPjJizszN MoTtV2FPT0WU
DOHH-2 NWLheHJMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4nUPWlEPTB;Nz60OFAzKM7:TR?= NX\2Z4l6W0GQR1XS
TGBC1TKB M{nz[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTWTWM2OD15LkS5PFk6KM7:TR?= MWPTRW5ITVJ?
GR-ST M4Thdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnTbG9WUUN3ME23MlUzPTl2IN88US=> MYTTRW5ITVJ?
KYSE-520 NVuzUlJmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYPqWmdiUUN3ME23MlU2PTF3IN88US=> NVjDTpViW0GQR1XS
CAPAN-1 M3vvZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTdwNUm1NUDPxE1? MVHTRW5ITVJ?
HCE-4 NUHXcY9LT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTdwNkKyO|kh|ryP MkjFV2FPT0WU
MLMA M3TLPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{DFWGlEPTB;Nz62Nlk2PyEQvF2= MlPUV2FPT0WU
HT-144 NFf4TJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGrDeXZKSzVyPUeuOlU{PjhizszN MULTRW5ITVJ?
KYSE-180 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\vOmlEPTB;Nz63NVE3QSEQvF2= Mnr5V2FPT0WU
TE-5 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGPiPWFKSzVyPUeuPVU6PzFizszN MnjpV2FPT0WU
IGROV-1 NWHTUFRkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LnTGlEPTB;Nz65PFU2OSEQvF2= NXvYVodGW0GQR1XS
NCI-H1581 NYTlO|dbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWHBOWhVUUN3ME24MlAyOiEQvF2= M4HJc3NCVkeHUh?=
SW1990 MnPuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRThwMES2OVkh|ryP M1jqenNCVkeHUh?=
EFM-19 MknzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRThwMEi1OFUh|ryP M1;WSXNCVkeHUh?=
OGR-1 Ml7sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1TLV2lEPTB;OD60N|AzOyEQvF2= NYLr[HVGW0GQR1XS
U-118-MG MojBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXvuZ5Z5UUN3ME24MlQ{PDZ|IN88US=> NX\2NFg6W0GQR1XS
SK-OV-3 Mo\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRThwNE[3OlUh|ryP NHHofHBUSU6JRWK=
KNS-62 NV[3fFRKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRThwNUG3OlEh|ryP MVnTRW5ITVJ?
GOTO MnnrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV6yU4EyUUN3ME24MlU4PjN3IN88US=> MnzsV2FPT0WU
8305C NELmPYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRThwN{C0PFQh|ryP MkXjV2FPT0WU
RPMI-2650 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRThwN{G5OVUh|ryP MYrTRW5ITVJ?
NEC8 NGiyW4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{HNUGlEPTB;OD63OFMxPyEQvF2= MYfTRW5ITVJ?
KYSE-450 M3TZ[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVj6dVlMUUN3ME24Mlg3PTR6IN88US=> NGTUNVhUSU6JRWK=
RMG-I M2Lwbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFm0R3BKSzVyPUmuNVQxPThizszN NFG4RWpUSU6JRWK=
CAKI-1 MmXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2XUZWlEPTB;OT6zNVk4QSEQvF2= Mn;lV2FPT0WU
KYSE-510 NILzc5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoW2TWM2OD17LkO1O|c5KM7:TR?= MmnvV2FPT0WU
A4-Fuk M1XlXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTlwM{[3NFEh|ryP NWHoPVNzW0GQR1XS
AN3-CA M3jUPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mle2TWM2OD17LkS1OFQ1KM7:TR?= NV;acnV4W0GQR1XS
SK-N-DZ NWfXcXZmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4fNO2lEPTB;OT63Nlg1QSEQvF2= MX3TRW5ITVJ?
HSC-2 NXv4W2psT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlfyTWM2OD17Lke2OlI6KM7:TR?= NU\BfmhxW0GQR1XS
EW-1 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnnkTWM2OD17Lke5N|Y6KM7:TR?= M1e2WXNCVkeHUh?=
D-566MG NUPvdo1lT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUnJVpJVUUN3ME25Mlg{PjZ2IN88US=> MmG2V2FPT0WU
COLO-792 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTlwOUi3OFYh|ryP MmTqV2FPT0WU
TE-10 MnX1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTFyLkCzPVYh|ryP MljjV2FPT0WU
NCI-H650 MmWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTFyLkSyPFYh|ryP MmHnV2FPT0WU
U-266 NUjCTXBFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFzoNXdKSzVyPUGwMlQ2PSEQvF2= NYrEcJNYW0GQR1XS
Detroit562 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2PiO2lEPTB;MUGuNFUyPSEQvF2= MVnTRW5ITVJ?
NH-12 NF76SIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlrpTWM2OD1zMT6xOFQ3KM7:TR?= MU\TRW5ITVJ?
CO-314 NWHFTZRuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoTZTWM2OD1zMT6yPFQzKM7:TR?= NV7yeIRjW0GQR1XS
IST-MEL1 M{fZRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHm0c|dKSzVyPUGxMlU{OjNizszN NVrv[G86W0GQR1XS
KNS-81-FD M32xVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWfJR|UxRTFzLkW1Nlch|ryP MVPTRW5ITVJ?
SW1463 NIDGOnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTFzLkW5PFkh|ryP NInzVJNUSU6JRWK=
NCI-H23 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWDFWXU5UUN3ME2xNU43PTV{IN88US=> MkS0V2FPT0WU
SK-MEL-2 NF7nSotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\hXGlEPTB;MUGuO|E6PyEQvF2= MVrTRW5ITVJ?
NB13 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHHHdFFKSzVyPUGyMlE1QTVizszN MVLTRW5ITVJ?
Daoy NH;SdYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4joS2lEPTB;MUKuNlg2PiEQvF2= M{DpPXNCVkeHUh?=
NCI-H1623 MoDxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2fJNWlEPTB;MUKuN|gxOSEQvF2= MUnTRW5ITVJ?
NMC-G1 NGrRV4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVTPTmFFUUN3ME2xNk44OTdizszN MV;TRW5ITVJ?
DK-MG Moi3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn7ITWM2OD1zMj65OFgzKM7:TR?= MWnTRW5ITVJ?
TCCSUP MlfCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NITV[WZKSzVyPUGzMlEzQDRizszN MlrTV2FPT0WU
SCC-15 NUS3TmZNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTF|LkK2OVEh|ryP MWXTRW5ITVJ?
NOS-1 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PrS2lEPTB;MUOuNlg6OyEQvF2= M1\6VXNCVkeHUh?=
RH-1 Mly4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWXxT201UUN3ME2xN{4{ODN5IN88US=> M3TObXNCVkeHUh?=
SK-MEL-3 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1nTeGlEPTB;MUOuN|czQCEQvF2= NYe5[|V{W0GQR1XS
NB5 NFf2dJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTafZBbUUN3ME2xN{41ODZ5IN88US=> NIfBUHFUSU6JRWK=
SNU-387 NHKyNIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTF|LkWwO|Ih|ryP NHLKbVdUSU6JRWK=
CAL-120 M3:0dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWTJTIRIUUN3ME2xN{43PzF6IN88US=> NV3LfZFbW0GQR1XS
Mo-T MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEjDRZVKSzVyPUGzMlcxPyEQvF2= MX\TRW5ITVJ?
LNCaP-Clone-FGC NEXibG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M33kPGlEPTB;MUOuO|k6OiEQvF2= MnTLV2FPT0WU
CAN M{PxfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV73WVM{UUN3ME2xOE4xOjh6IN88US=> M2niWXNCVkeHUh?=
SK-MEL-30 NXfsNYM2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPMTWM2OD1zND6wOlMh|ryP NX\sbotOW0GQR1XS
COLO-678 NIrqWldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF7MWZNKSzVyPUG0MlA5OjJizszN NIH5[pVUSU6JRWK=
SCC-9 M1r5VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTF2LkGwNlEh|ryP NEXB[XdUSU6JRWK=
KINGS-1 NVnTXVU{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2DDcGlEPTB;MUSuNVQxOiEQvF2= M3\IdHNCVkeHUh?=
SL-513 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTF2LkG4O{DPxE1? NETSc4VUSU6JRWK=
HLE MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTF2LkO4OVIh|ryP MmG5V2FPT0WU
SW1573 NIHSfnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml7DTWM2OD1zND60OFM2KM7:TR?= MWjTRW5ITVJ?
KYSE-140 M{Hz[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTF2Lk[zNlch|ryP NI\KZZlUSU6JRWK=
SK-PN-DW M4KyS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRTF2LkiwNFEh|ryP NGD3THVUSU6JRWK=
A253 NHPs[|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTF3LkC2NlUh|ryP MYXTRW5ITVJ?
CAL-12T NXmyWJZtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFPTPJdKSzVyPUG1MlQ3PjJizszN MoXDV2FPT0WU
COLO-679 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml[1TWM2OD1zNT63Olg{KM7:TR?= NGDJPYFUSU6JRWK=
UACC-257 NYDI[ZBWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4ThWmlEPTB;MU[uNVIxOSEQvF2= MmSyV2FPT0WU
U-87-MG MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\xc2lEPTB;MU[uN|UzOyEQvF2= NHrx[pFUSU6JRWK=
HCC1806 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoTPTWM2OD1zNj63NFcyKM7:TR?= M1vNPXNCVkeHUh?=
NCI-H2170 NVvjclkxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnrWTWM2OD1zNz6yOFQ5KM7:TR?= MoDRV2FPT0WU
AGS NX3ENG1zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnLmTWM2OD1zNz6zPFA5KM7:TR?= MW\TRW5ITVJ?
MEL-HO M1TJcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoHMTWM2OD1zNz63OVA{KM7:TR?= MXTTRW5ITVJ?
SW48 M1exeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEH6PJNKSzVyPUG3Mlc4OTZizszN NHjWdG1USU6JRWK=
HuP-T4 Mo[wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;4VmpQUUN3ME2xPE4xOjB4IN88US=> M3fDdHNCVkeHUh?=
NCI-H720 NYTzc|U5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXu2[m5MUUN3ME2xPE4yPDB{IN88US=> NXLESI5XW0GQR1XS
RCC10RGB NHjIdGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlnQTWM2OD1zOD6xOlk4KM7:TR?= M4HFcXNCVkeHUh?=
HD-MY-Z M{jPeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\0c5ZKSzVyPUG4MlIzPTRizszN NWPpRmR1W0GQR1XS
A427 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4K0VWlEPTB;MUiuOVA6PCEQvF2= MW\TRW5ITVJ?
HCC2998 MoDwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVHPWnV[UUN3ME2xPE43ODVzIN88US=> MWnTRW5ITVJ?
EPLC-272H M4TKT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1rhUGlEPTB;MUmuNFQ{PCEQvF2= MnnLV2FPT0WU
C32 NFXk[JpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHTQ[4lKSzVyPUG5MlA1PSEQvF2= Ml3wV2FPT0WU
UMC-11 MnewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYX3SZFrUUN3ME2xPU4zOTJ|IN88US=> NGrLWIRUSU6JRWK=
CaR-1 NEHhW3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTF7Lk[4NFQh|ryP NGfpR4VUSU6JRWK=
KYSE-410 MoDLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1q5VGlEPTB;MUmuPVE{QSEQvF2= M3LCbXNCVkeHUh?=
HuCCT1 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXyxfmMyUUN3ME2yNE43Ojl2IN88US=> M1ntcXNCVkeHUh?=
LB996-RCC NES5dlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGHyPI5KSzVyPUKwMlcyPjhizszN MYnTRW5ITVJ?
KYSE-70 Mk[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFfCeXVKSzVyPUKwMlgxPTlizszN MXXTRW5ITVJ?
CAL-72 M1OwRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTJyLkmxOUDPxE1? MoLTV2FPT0WU
Capan-2 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTJzLkC0NVMh|ryP MXjTRW5ITVJ?
PANC-08-13 NYL6OmEyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4PHNmlEPTB;MkGuNlUyPSEQvF2= MWfTRW5ITVJ?
SBC-1 NXz1W40zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTJzLkOwPFEh|ryP MmWwV2FPT0WU
MFM-223 NV\RZpZWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHnocGtKSzVyPUKxMlM{PDJizszN M3S3TnNCVkeHUh?=
BB49-HNC NYnSeHdqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlK1TWM2OD1{MT61O|E3KM7:TR?= NF7vXGhUSU6JRWK=
SH-4 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFPSem5KSzVyPUKxMlY3OThizszN M4f6S3NCVkeHUh?=
HuO9 M{e0dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTJzLkm4NlUh|ryP Ml3nV2FPT0WU
AM-38 MmPSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\nNmlEPTB;MkKuNFQ5PSEQvF2= NXfYNm1jW0GQR1XS
A431 NFjEXZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTJ|LkKxNVkh|ryP M3;HeXNCVkeHUh?=
YAPC MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\lVVNTUUN3ME2yN{4zPjVzIN88US=> MW\TRW5ITVJ?
LU-139 NGrxUplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3fpT2lEPTB;MkOuOFgxQSEQvF2= M1GzT3NCVkeHUh?=
HEC-1 NFn4[GpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYfwPIxCUUN3ME2yN{41QTN5IN88US=> M4Dq[XNCVkeHUh?=
SCC-25 Mli0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHjwXZlKSzVyPUK0MlMxODZizszN MVvTRW5ITVJ?
HT-29 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3nUSWlEPTB;MkSuN|gzOyEQvF2= NXzCSnNIW0GQR1XS
PC-14 M2Hqd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEXxbHhKSzVyPUK0MlY2PzFizszN MnfCV2FPT0WU
Calu-6 M{\YcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHrkOmpKSzVyPUK1MlUxPzFizszN MlTuV2FPT0WU
SJRH30 NHrKc|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYK2VmxwUUN3ME2yOU43PDl4IN88US=> MnjiV2FPT0WU
ChaGo-K-1 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\QOGlEPTB;Mk[uNVYzQSEQvF2= M{TjbnNCVkeHUh?=
IA-LM NXq4fmRNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoruTWM2OD1{Nj6zOlQ2KM7:TR?= NXq3e5REW0GQR1XS
GP5d MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M37OU2lEPTB;Mk[uOFQ6OSEQvF2= MYfTRW5ITVJ?
NCI-H2291 M{LmTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUPRVYIxUUN3ME2yOk43PTRzIN88US=> MWPTRW5ITVJ?
BALL-1 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M37QXWlEPTB;Mk[uPVM6PyEQvF2= M3f2fHNCVkeHUh?=
HCC1954 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHfXUXdKSzVyPUK2Mlk5ODhizszN MnjPV2FPT0WU
NCI-H2452 MkDWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\sWVFuUUN3ME2yO{41OTZ|IN88US=> MWPTRW5ITVJ?
LU-99A M2jzb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MontTWM2OD1{Nz61OVgzKM7:TR?= M4fv[nNCVkeHUh?=
NTERA-S-cl-D1 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX;QS4g3UUN3ME2yO{44Ojl7IN88US=> NIrLWmZUSU6JRWK=
PANC-10-05 MkT4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlvjTWM2OD1{Nz63O|c2KM7:TR?= Mn3CV2FPT0WU
NCI-H2405 MmPXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWeyWnRmUUN3ME2yO{46Ozh5IN88US=> M2XkXnNCVkeHUh?=
MDA-MB-415 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;nd4xuUUN3ME2yPE41OTN5IN88US=> NHHoNGpUSU6JRWK=
NCI-H2342 MnzTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3f6XGlEPTB;MkiuOVI5OSEQvF2= NX3jS3VoW0GQR1XS
TGBC24TKB NIfjPGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4G0V2lEPTB;MkiuO|EyPyEQvF2= MkHzV2FPT0WU
LU-134-A Mn7yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVHJR|UxRTJ6LkmyOlEh|ryP Mo\DV2FPT0WU
SCC-4 NWLuR2Y4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NETm[WlKSzVyPUOxMlA1QTRizszN NYjBb3lkW0GQR1XS
Saos-2 Ml7MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NInhTZZKSzVyPUOxMlk{ODZizszN Mnq0V2FPT0WU
RERF-LC-MS M{LGVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13oRWlEPTB;M{KuPFI{OSEQvF2= NFv1ZotUSU6JRWK=
M14 NG[yVJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\FNZZKSzVyPUOyMlk4PjRizszN MlnVV2FPT0WU
HPAF-II M3TXWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXHZ25FUUN3ME2zN{42ODFzIN88US=> M3nH[3NCVkeHUh?=
NCI-H1755 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTN2LkOzNFUh|ryP NFrPXGlUSU6JRWK=
D-392MG MlH3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn75TWM2OD1|NT64Olc1KM7:TR?= MXHTRW5ITVJ?
A704 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlL5TWM2OD1|Nj6wOFI4KM7:TR?= NVfVO|dRW0GQR1XS
CP50-MEL-B MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWPrXmlJUUN3ME2zOk4yQTFzIN88US=> MXHTRW5ITVJ?
EW-18 NVPFbZlGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIfBVFFKSzVyPUO2MlQ2OiEQvF2= NFnvb5JUSU6JRWK=
WM-115 NI\Reo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGTmR3pKSzVyPUO2MlgxQTlizszN NEDQdFlUSU6JRWK=
LU-65 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTN5LkG0NVch|ryP M3j3fXNCVkeHUh?=
NCI-H1563 NIDSXFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4Sw[mlEPTB;M{euNlQ5PCEQvF2= NYLWZ5RWW0GQR1XS
DBTRG-05MG MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUfY[HJqUUN3ME2zPE4xPjlzIN88US=> NX7sSWVCW0GQR1XS
NCI-H630 MmTSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTN6LkS3NVQh|ryP NYPZOGI1W0GQR1XS
NCI-H1155 NVi1S|RPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2TnS2lEPTB;M{muNlQzKM7:TR?= MWXTRW5ITVJ?
OVACR-3 M4\yW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnLITWM2OD1|OT65NVk2KM7:TR?= NG\H[mtUSU6JRWK=
OAW-42 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1zzTWlEPTB;NECuOFI2QCEQvF2= MlPHV2FPT0WU
JVM-2 NViz[4o1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYHQVGZGUUN3ME20NU4zPDF3IN88US=> M2rYT3NCVkeHUh?=
C3A MkOyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXjDdIhyUUN3ME20NU4{PDR5IN88US=> NX61W49EW0GQR1XS
HT55 M4jMSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTR{LkK4OFEh|ryP M{jvR3NCVkeHUh?=
OVCAR-4 NXrIUHJVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTR{LkK5O|Qh|ryP NFPRZZhUSU6JRWK=
MEG-01 NVzX[VFrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTR{LkS2NVYh|ryP MoK2V2FPT0WU
NCI-H82 Mn34S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTR|Lkm4PVIh|ryP M3v2[3NCVkeHUh?=
JEG-3 NFjCPGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFfOWmNKSzVyPUS0Mlk1PyEQvF2= M1\QNHNCVkeHUh?=
BPH-1 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUPsboVxUUN3ME20Ok4{QTl6IN88US=> NEnOV4dUSU6JRWK=
MPP-89 NUXhOWk{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTR5LkK4PVgh|ryP NIe4dpFUSU6JRWK=
ALL-PO MnvVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjqfWJQUUN3ME20O{41OTh6IN88US=> M{TzU3NCVkeHUh?=
HT MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI\Md21KSzVyPUS3MlQ6OiEQvF2= MVTTRW5ITVJ?
NCI-H2347 M3\XTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnrQTWM2OD12OD6wO|E2KM7:TR?= MUXTRW5ITVJ?
A2780 NGjnV2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2jSdWlEPTB;NEmuOFIzQCEQvF2= NV7hO5o1W0GQR1XS
KARPAS-299 Mo\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\3[Ho3UUN3ME20PU42OTF7IN88US=> NFv2OJBUSU6JRWK=
NCI-H1651 NHrGVVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYrKcndwUUN3ME20PU45QDJzIN88US=> Mnm4V2FPT0WU

... Click to View More Cell Line Experimental Data

In vivo PD 0332991 indicates complete tumor stasis in a MDA-MB-435 xenograft at 150 mg/kg. PD 0332991 also shows broad-spectrum antitumor activity in multiple human tumor xenografts by eliminating phospho-Rb and the proliferative marker Ki-67 from tumor tissue and down-regulation of genes under the transcriptional control of E2F. [1]

Protocol

Kinase Assay:

[1]

+ Expand

Cdk Assays:

A stock solution of PD0332991 is prepared in DMSO. CDK assays are performed in 96-well filter plates. All CDK-cyclin kinase complexes are expressed in insect cells through baculovirus infection and purified. The substrate for the assays is a fragment (amino acids 792–928) of pRb fused to GST (GST·RB-Cterm). The total volume in each well is 0.1 mL containing a final concentration of 20 mM Tris-HCl, pH 7.4, 50 mM NaCl, 1 mM dithiothreitol, 10 mM MgCl2, 25 μM ATP (for CDK4-cyclin D1, CDK6-cyclin D2, and CDK6-cyclin D3) or 12 μM ATP (for CDK2-cyclin E, CDK2-cyclin A, and CDC2-cyclin B) containing 0.25 μCi of [γ-32P]ATP, 20 ng of enzyme, 1 μg of GST·RB-Cterm, and PD 0332991 (0.001-0.1μM). All components except the [γ-32P]ATP are added to the wells, and the plate is placed on a plate mixer for 2 min. The reaction is started by adding the [γ-32P]ATP and the plate is incubated at 25 °C for 15 min. The reaction is terminated by addition of 0.1 mL of 20% trichloroacetic acid and the plate is kept at 4  °C for at least 1 hour to allow the substrate to precipitate. The wells are then washed 5 times with 0.2 mL of 10% trichloroacetic acid and radioactive incorporation is determined with a β plate counter.
Cell Research:

[1]

+ Expand
  • Cell lines: Tumor cell lines including MDA-MB-435, ZR-75-1, T-47D, MCF-7, H1299, Colo-205, MDA-MB-468, H2009, CRRF-CEM and K562
  • Concentrations: 0.01-1 μM
  • Incubation Time: 24 hours
  • Method:

    Cells are seeded at 2 × 104 per well in a 96-well plate and incubated overnight. PD 0332991 (0.01-1 μM) is added to the wells and incubated at 37 °C for another 24 hours. [14C]Thymidine (0.1 μCi) is added to each well and incorporation of the radiolabel is allowed to proceed for 72 hours. Incorporated radioactivity is determined with a β plate counter.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: Advanced stage human tumor xenografts including Colo-205, MDA-MB-435 breast, SF-295 glioblastoma, ZR-75-1 breast, PC-3 prostate, H125 lung, SW-620 colon, H23 lung and MDA-MB-468 breast (Rb negative) are established in severe combined immunodeficient mice.
  • Formulation: Dissolved in sodium lactate buffer (50 mM, pH 4.0)
  • Dosages: 0-150 mg/kg
  • Administration: Given by gavage
    (Only for Reference)

Solubility (25°C)

In vitro Water 30 mg/mL (61.98 mM)
DMSO 3 mg/mL warmed (6.19 mM)
Ethanol Insoluble
In vivo Add solvents individually and in order:
Saline
20 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 483.99
Formula

C24H29N7O2.HCl

CAS No. 827022-32-2
Storage powder
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03007979 Not yet recruiting Breast Cancer|Breast Carcinoma|Cancer of Breast|Malignant Tumor of Breast Washington University School of Medicine February 28, 2017 Phase 2
NCT02907918 Not yet recruiting Breast Cancer|Cancer of Breast|Breast Carcinoma Washington University School of Medicine|Pfizer February 28, 2017 Phase 2
NCT01209598 Completed Sarcoma|Liposarcoma Memorial Sloan Kettering Cancer Center|Pfizer September 23, 2010 Phase 2
NCT03054363 Not yet recruiting Breast Cancer University of Colorado, Denver March 2017 Phase 1|Phase 2
NCT03024489 Not yet recruiting Head and Neck Cancer|Locally Advanced|Unresectable Mahidol University February 2017 Phase 1|Phase 2
NCT02947685 Not yet recruiting HER-2 Positive Breast Cancer|Estrogen Receptor Positive Breast Cancer Alliance Foundation Trials, LLC.|Pfizer|German Breast Group (GBG)|Fondazione Michelangelo|PrECOG, LLC.|The Australia and New Zealand Breast Cancer Trials Group (ANZBCTG)|Alliance Foundation Trials Biorepository - Washington State University|Alliance Foundation Trials Central Imaging Core Lab - Ohio State University|Mastering Breast Cancer Initiative, LLC|Mayo Clinic Statistics and Data Center|INC Research|SOLTI Breast Cancer Research Group February 2017 Phase 3

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    There are two kind of Palbociclibs available: the isethionate salt or the HCl salt. I would like to know which is the main difference between them and what are they more suitable for in terms of experiment type (cell culture or in vivo animals experiments).

  • Answer:

    This two compounds are different Palbociclib salt. S1579 is the Isethionate salt, and the S1116 is the HCl salt. you can use S1116 for oral administration while S1579 is more suitable for I.P. administration.

CDK Signaling Pathway Map

CDK Inhibitors with Unique Features

Related CDK Products

Tags: buy Palbociclib (PD-0332991) HCl | Palbociclib (PD-0332991) HCl supplier | purchase Palbociclib (PD-0332991) HCl | Palbociclib (PD-0332991) HCl cost | Palbociclib (PD-0332991) HCl manufacturer | order Palbociclib (PD-0332991) HCl | Palbociclib (PD-0332991) HCl distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID